Wall Street analysts predict that Cascadian Therapeutics Inc (NASDAQ:CASC) will post earnings per share of ($0.29) for the current quarter, Zacks reports. Zero analysts have provided estimates for Cascadian Therapeutics’ earnings. Cascadian Therapeutics reported earnings per share of ($0.47) during the same quarter last year, which suggests a positive year-over-year growth rate of 38.3%. The firm is expected to report its next earnings report on Thursday, March 8th.
According to Zacks, analysts expect that Cascadian Therapeutics will report full year earnings of ($1.27) per share for the current fiscal year, with EPS estimates ranging from ($1.53) to ($1.14). For the next financial year, analysts forecast that the business will report earnings of ($1.03) per share, with EPS estimates ranging from ($1.22) to ($0.69). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow Cascadian Therapeutics.
Cascadian Therapeutics (NASDAQ:CASC) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.29) by $0.01. During the same quarter in the prior year, the firm posted ($0.09) EPS.
Separately, Zacks Investment Research raised shares of Cascadian Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 price objective for the company in a research report on Monday, November 13th. Three analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $5.63.
Cascadian Therapeutics (NASDAQ:CASC) traded up $0.15 on Wednesday, reaching $4.07. 271,162 shares of the company traded hands, compared to its average volume of 285,624. Cascadian Therapeutics has a 1-year low of $3.18 and a 1-year high of $4.97. The company has a market capitalization of $198.20, a PE ratio of -3.01 and a beta of 2.30.
A number of institutional investors and hedge funds have recently bought and sold shares of CASC. Schwab Charles Investment Management Inc. bought a new stake in Cascadian Therapeutics during the second quarter worth about $225,000. Rhumbline Advisers acquired a new position in Cascadian Therapeutics during the second quarter worth about $143,000. State of Wisconsin Investment Board acquired a new position in Cascadian Therapeutics during the second quarter worth about $104,000. Bank of New York Mellon Corp raised its stake in Cascadian Therapeutics by 649.9% during the second quarter. Bank of New York Mellon Corp now owns 154,575 shares of the biopharmaceutical company’s stock worth $574,000 after acquiring an additional 133,962 shares in the last quarter. Finally, Teachers Advisors LLC acquired a new position in Cascadian Therapeutics during the second quarter worth about $252,000. 80.33% of the stock is owned by institutional investors and hedge funds.
WARNING: This report was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/20/0-29-earnings-per-share-expected-for-cascadian-therapeutics-inc-casc-this-quarter.html.
About Cascadian Therapeutics
Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.
Get a free copy of the Zacks research report on Cascadian Therapeutics (CASC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cascadian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.